dc.creator | SPOSITO, Andrei C. | |
dc.creator | RAMIRES, Jose A. F. | |
dc.creator | JUKEMA, J. Wouter | |
dc.creator | MOLINA, Juan Carlos | |
dc.creator | SILVA, Pedro Marques da | |
dc.creator | GHADANFAR, Mathieu M. | |
dc.creator | WILSON, Peter W. F. | |
dc.date.accessioned | 2012-10-19T17:17:38Z | |
dc.date.accessioned | 2018-07-04T15:06:10Z | |
dc.date.available | 2012-10-19T17:17:38Z | |
dc.date.available | 2018-07-04T15:06:10Z | |
dc.date.created | 2012-10-19T17:17:38Z | |
dc.date.issued | 2009 | |
dc.identifier | CURRENT MEDICAL RESEARCH AND OPINION, v.25, n.5, p.1171-1178, 2009 | |
dc.identifier | 0300-7995 | |
dc.identifier | http://producao.usp.br/handle/BDPI/21837 | |
dc.identifier | 10.1185/03007990902846423 | |
dc.identifier | http://dx.doi.org/10.1185/03007990902846423 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1618611 | |
dc.description.abstract | Objective: To evaluate physicians` attitudes and adherence to the use of risk scores in the primary prevention of cardiovascular disease (CVD). Design and methods: A cross-sectional survey of 2056 physicians involved in the primary prevention of CVD. Participants included cardiologists (47%), general practitioners (42%), and endocrinologists (11%) from several geographical regions: Brazil (n=968), USA (n=381), Greece (n=275), Chile (n=157), Venezuela (n=128), Portugal (n=42), The Netherlands (n=41), and Central America (Costa Rica, Panama, El Salvador and Guatemala; n=64). Results: The main outcome measure was the percentage of responses on a multiple-choice questionnaire describing a hypothetical asymptomatic patient at intermediate risk for CVD according to the Framingham Risk Score. Only 48% of respondents reported regular use of CVD risk scores to tailor preventive treatment in the case scenario. Of non-users, nearly three-quarters indicated that `It takes up too much of my time` (52%) or `I don`t believe they add value to the clinical evaluation` (21%). Only 56% of respondents indicated that they would prescribe lipid-lowering therapy for the hypothetical intermediate-risk patient. A significantly greater proportion of regular users than non-users of CVD risk scores identified the need for lipid-lowering therapy in the hypothetical patient (59 vs. 41%; p<0.0001). | |
dc.language | eng | |
dc.publisher | LIBRAPHARM/INFORMA HEALTHCARE | |
dc.relation | Current Medical Research and Opinion | |
dc.rights | Copyright LIBRAPHARM/INFORMA HEALTHCARE | |
dc.rights | closedAccess | |
dc.subject | Cardiovascular risk | |
dc.subject | Dyslipidemia | |
dc.subject | Lipid-lowering therapy | |
dc.subject | Primary prevention | |
dc.title | Physicians` attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions | |
dc.type | Artículos de revistas | |